Pherecydes Pharma
Develops precision phage therapy to treat resistant bacterial infections.
ALPHE | PA
Overview
Corporate Details
- ISIN(s):
- FR0011651694
- LEI:
- 894500LYT3UUN58X3I68
- Country:
- France
- Address:
- 22 BD BENONI GOULLIN, NANTES BIOTECH, 44200 NANTES
- Sector:
- Professional, scientific and technical activities
- Industry:
- Research and experimental development on natural sciences and engineering
Description
Pherecydes Pharma is a biotechnology company that specializes in developing treatments for resistant bacterial infections. The company pioneers precision phage therapy, an approach that uses bacteriophage viruses (phages) to specifically target and combat harmful bacteria. This personalized therapeutic strategy is designed to treat severe and complicated infections that are unresponsive to conventional antibiotics. Founded in 2006, the company focuses on creating a portfolio of phages effective against critical bacterial pathogens. In June 2023, Pherecydes Pharma merged with Erytech Pharma to become Phaxiam Therapeutics, continuing its work in the fight against antimicrobial resistance.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2023-06-23 20:45 |
AGM Information
Informations privilégiées / Autres communiqués
|
French | 214.3 KB | ||
| 2023-06-23 20:45 |
AGM Information
Inside Information / Other news releases
|
English | 213.8 KB | ||
| 2023-06-14 20:00 |
Legal Proceedings Report
Inside Information / Other news releases
|
English | 197.1 KB | ||
| 2023-06-14 20:00 |
Legal Proceedings Report
Informations privilégiées / Autres communiqués
|
French | 200.6 KB | ||
| 2023-06-08 07:30 |
Legal Proceedings Report
Informations privilégiées / Autres communiqués
|
French | 297.3 KB | ||
| 2023-06-08 07:30 |
Regulatory Filings
Inside Information / Other news releases
|
English | 269.4 KB | ||
| 2023-06-05 08:00 |
Legal Proceedings Report
Inside Information / Other news releases
|
English | 198.4 KB | ||
| 2023-06-05 08:00 |
Legal Proceedings Report
Informations privilégiées / Autres communiqués
|
French | 192.1 KB | ||
| 2023-06-02 20:00 |
Pre-Annual General Meeting Information
Modalités de mise à disposition des documents préparatoires à l'AG
|
French | 152.4 KB | ||
| 2023-05-23 23:43 |
M&A Activity
News releases during takeover bids / Takeover bids Other news releases
|
English | 191.8 KB | ||
| 2023-05-23 23:43 |
Registration Form
Communiqués publiés en période d'offre publique d'acquisition / OPA Autres comm…
|
French | 184.9 KB | ||
| 2023-05-16 07:00 |
M&A Activity
Inside Information / Other news releases
|
English | 224.2 KB | ||
| 2023-05-16 07:00 |
M&A Activity
Informations privilégiées / Autres communiqués
|
French | 216.3 KB | ||
| 2023-05-11 18:00 |
Capital/Financing Update
Acquisition ou cession des actions de l'émetteur / Information relative au cont…
|
French | 200.6 KB | ||
| 2023-04-27 18:00 |
Report Publication Announcement
Rapports financiers et d'audit annuels / Modalités de mise à disposition du rap…
|
French | 195.2 KB |
Automate Your Workflow. Get a real-time feed of all Pherecydes Pharma filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Pherecydes Pharma
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Pherecydes Pharma via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
%20Co.%2C%20Ltd/other/SLSBioSpecialty_Lab_Solution_Bio_Co._Ltd-logo.jpg){kind=logo}
